Novartis AG (NYSE:NVS) shares gained 17% YTD but dropped 2.5% in July after Q1 earnings fell short of analyst estimates. Operating profit exceeded expectations at $5.93 billion. Jim Cramer questioned whether CEO Dr. Vasant Narasimhan is leaving the company, raising concerns about the future of the pharmaceutical giant.

Loomis Sayles Global Growth Fund highlighted Novartis AG (NYSE:NVS) in its Q1 2025 investor letter, emphasizing the company’s diversified market leadership in various healthcare sectors. Following recent spinoffs, Novartis now focuses solely on innovative medicines, generating over 50% of revenue from the Americas and around 30% from Europe.

While Novartis AG (NVS) shows potential as an investment, some AI stocks may offer higher returns with limited downside risk. Investors seeking an affordable AI stock with significant potential amid Trump tariffs and onshoring can explore the best short-term AI stock. For more insights, check out reports on stocks poised to double in 3 years and hidden AI stocks to buy now.

Read more at Yahoo Finance: Jim Cramer Wonders Whether Its CEO Is Leaving